Table 2.
Outcome and toxicities
| DLBCL | MCL | HL | PCNSL | Total | |
|---|---|---|---|---|---|
| No. of patients | 80 | 75 | 47 | 45 | 247 |
| Leukocyte engraftment (day after ASCT) | |||||
| Median | 10 | 10 | 10 | 10 | 10 |
| Range | 8–21 | 8–24 | 7–13 | 8–35 | 7–35 |
| Platelet engraftment (day after ASCT) | |||||
| Median | 13 | 13 | 12 | 11 | 13 |
| Range | 7–42 | 8–29 | 7–16 | 7–25 | 7–42 |
| Adverse events grade ≥ 3 CTCAE | |||||
| Nausea | 4 (5) | 2 (3) | 0 | 4 (9) | 10 (4) |
| Mucositis | 31 (39) | 26 (35) | 10 (27) | 20 (44) | 87 (35) |
| Infection | 60 (75) | 57 (76) | 37 (79) | 37 (82) | 191 (77) |
| Renal toxicity | 1 (1) | 0 | 0 | 1 (2) | 2 (1) |
| Liver toxicity | 1 (1) | 1 (1) | 0 | 0 | 2 (1) |
| Others1 | 2 (3) | 2 (3) | 3 (6) | 3 (7) | 10 (4) |
| Remission status after ASCT [no. (%)] | |||||
| Complete remission3 | 60 (75) | 68 (91) | 34 (72) | 35 (78) | 197 (80) |
| Partial remission | 12 (15) | 4 (5) | 6 (13) | 6 (13) | 28 (11) |
| Progressive disease | 3 (4) | 1 (1) | 0 | 3 (7) | 7 (3) |
| Unknown | 5 (6) | 2 (3) | 7 (15) | 1 (2) | 15 (6) |
| Relapse [no. (%)] | 22 (28) | 24 (32) | 11 (23) | 11 (24) | 68 (28) |
| Follow-up allogeneic SCT [no. (%)] | 10 (13) | 7 (9) | 14 (30) | 0 | 31 (16) |
| Death [no. (%)] | 35 (44) | 20 (27) | 8 (17) | 12 (27) | 75 (30) |
| Reasons of death [no. (% of deaths)] | |||||
| Lymphoma-related | 22 (63) | 12 (60) | 5 (62) | 9 (75) | 48 (64) |
| Infection | 6 (17) | 7 (35) | 3 (38) | 1 (8) | 17 (23) |
| Cardiac event | 2 (6) | 0 | 0 | 1 (8) | 3 (4) |
| Second neoplasia | 2 (6) | 0 | 0 | 1 (8) | 3 (4) |
| Others2 | 2 (6) | 1 (5) | 0 | 0 | 3 (4) |
| Not known | 1 (3) | 0 | 0 | 0 | 1 (1) |
1Anaphylaxis, ARDS, atrial fibrillation, atrial flutter, graft failure, neurologic deficit, seizure, thrombosis
2Hypoxia caused by aspiration, cerebral aneurysm, respiratory failure with unclear interstitial lung disease
3Including patients with CR pre-ASCT
DLBCL diffuse large B-cell lymphoma, MCL mantle cell lymphoma, HL Hodgkin lymphoma, PCNSL primary CNS lymphoma, ASCT autologous stem cell transplantation